Patents-Review.com
ClassID:

109886 ⎘

C12N2710/16621 - CPC Classification

Classification description:

dsDNA viruses; Details; Herpesviridae; Simplexvirus, e.g. human herpesvirus 1, 2 Viruses as such, e.g. new isolates, mutants or their genomic sequences

Recent Application in this class:
#1
20260116934
2026-04-30

Compositions and Methods for Delivering CFTR Polypeptides

 #2
20260077006
2026-03-19

ONCOLYTIC VIRUS EXPRESSING AN IMMUNE CELL ENGAGER FOR TUMOR TARGETING

 #3
20260053872
2026-02-26

ADOPTIVE CELLULAR THERAPY

 #4
20250367279
2025-12-04

RECOMBINANT HERPES SIMPLEX VIRUS-2 EXPRESSING GLYCOPROTEIN D AND B ANTIGENS

 #5
20250352646
2025-11-20

ENGINEERED VIRUS

 #6
20250339482
2025-11-06

Recombinant Herpes Simplex Virus for Cancer Immunotherapy

 #7
20250319144
2025-10-16

Recombinant Armed Oncolytic Virus Composition and Use Thereof in TIL Adoptive Therapy

 #8
20250295719
2025-09-25

IL-27 EXPRESSING ONCOLYTIC VIRUSES

 #9
20250255797
2025-08-14

Recombinant Nucleic Acids Encoding Cosmetic Protein(s) For Aesthetic Applications

 #10
20250134941
2025-05-01

HSV-1 ONCOLYTIC VIRUS THERAPIES THAT SPECIFICALLY KILL ALT DEPENDENT CANCERS

 #11
20250109411
2025-04-03

NON-TOXIC HSV VECTORS FOR EFFICIENT GENE DELIVERY APPLICATIONS AND COMPLEMENTING CELLS FOR THEIR PRODUCTION

 #12
20250009822
2025-01-09

ADOPTIVE CELLULAR THERAPY

 #13
20240301365
2024-09-12

ONCOLYTIC VIRUS STRAIN

 #14
20240216533
2024-07-04

HERPES SIMPLEX VIRUS AND USE THEREOF

 #15
20240174986
2024-05-30

MUTANT HERPESVIRUS AND VACCINE COMPOSITIONS

 #16
20240158809
2024-05-16

High-transducing HSV vectors

 #17
20240018488
2024-01-18

MODIFIED ONCOLYTIC VIRUS

 #18
20230372472
2023-11-23

IMMUNOTHERAPEUTIC VIRUS FOR THE TREATMENT OF CANCER

 #19
20230365994
2023-11-16

HSV VECTORS WITH ENHANCED REPLICATION IN CANCER CELLS

 #20
20230338443
2023-10-26

EXPRESSION OF PTEN-LONG WITH ONCOLYTIC VIRUSES

 #21
20230270846
2023-08-31

Replication-competent controlled alpha-herpesvirus vectors and uses therefore

 #22
20230242887
2023-08-03

ONCOLYTIC VIRUS CARRYING E-CADHERIN AND USES THEREOF

 #23
20230212531
2023-07-06

ENGINEERED VIRUS

 #24
20230203453
2023-06-29

MODIFIED ONCOLYTIC VIRUS

 #25
20230192852
2023-06-22

Virus composition

 #26
20230130992
2023-04-27

Oncolytic virus strain

 #27
20230115116
2023-04-13

ONCOLYTIC VIRAL VECTORS AND USES THEREOF

 #28
20230026342
2023-01-26

NEW GENERATION REGULATABLE FUSOGENIC ONCOLYTIC HERPES SIMPLEX VIRUS TYPE 1 VIRUS AND METHODS OF USE

 #29
20220409684
2022-12-29

CODON OPTIMIZED NEW GENERATION REGULATABLE FUSOGENIC ONCOLYTIC HERPES SIMPLEX VIRUS TYPE 1 VIRUS AND METHODS OF USE

 #30
20220213508
2022-07-07

NON-TOXIC HSV VECTORS FOR EFFICIENT GENE DELIVERY APPLICATIONS AND COMPLEMENTING CELLS FOR THEIR PRODUCTION

 #31
20220154149
2022-05-19

SYNCYTIAL ONCOLYTIC HERPES SIMPLEX MUTANTS AS POTENT CANCER THERAPEUTICS

 #32
20220153843
2022-05-19

Bispecific single-chain antibody, recombinant oncolytic virus for expressing same and virus composition

 #33
20220002680
2022-01-06

REGULATABLE FUSOGENIC ONCOLYTIC HERPES SIMPLEX VIRUS TYPE 1 VIRUS AND METHODS OF USE

 #34
20210369838
2021-12-02

Methods of using HSV-2 single cycle virus delta-gD and HSV-2 recombinant glycoprotein D

 #35
20210317174
2021-10-14

COMPOSITIONS AND METHODS FOR DELIVERING CFTR POLYPEPTIDES

 #36
20210254019
2021-08-19

Engineered virus

 #37
20210252084
2021-08-19

Adoptive cellular therapy

 #38
20210171591
2021-06-10

CODON OPTIMIZED NUCLEIC ACID ENCODING A RETINITIS PIGMENTOSA GTPASE REGULATOR (RPGR)

 #39
20210138009
2021-05-13

Recombinant Herpes Simplex Virus for Cancer Immunotherapy

 #40
20210138007
2021-05-13

Oncolytic HSV vector

 #41
20210121513
2021-04-29

Antigenically Stealthed Oncolytic Viruses

 #42
20210107946
2021-04-15

Recombinant Herpes Simplex Virus-2 expressing glycoprotein B and D antigens

 #43
20210087245
2021-03-25

COMPOSITIONS AND METHODS FOR DELIVERING CFTR POLYPEPTIDES

 #44
20210052680
2021-02-25

Stable Frozen Virus Formulation

 #45
20210045988
2021-02-18

Recombinant nucleic acids encoding cosmetic protein(s) for aesthetic

 #46
20200405792
2020-12-31

Construction of oncolytic herpes simplex viruses (oHSV) obligate vector and constructs for cancer therapy

 #47
20200376114
2020-12-03

Recombinant herpes simplex virus 2 (HSV-2) vaccine vectors

 #48
20200263147
2020-08-20

Non-neuroinvasive viruses and uses thereof

 #49
20200263146
2020-08-20

Non-neuroinvasive viruses and uses thereof

 #50
20200254060
2020-08-13

Compositions and methods for delivering CFTR polypeptides

 #51
20200208122
2020-07-02

Oncolytic virus strain

 #52
20200206314
2020-07-02

HSV vectors for delivery of NT3 and treatment of CIPN

 #53
20200199618
2020-06-25

High-transducing HSV vectors

 #54
20200199542
2020-06-25

Modified oncolytic virus

 #55
20200149067
2020-05-14

RECOMBINANT HERPES SIMPLEX VIRUS, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF

 #56
20200147189
2020-05-14

Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-HSV receptors

 #57
20200147156
2020-05-14

Oncolytic viral vectors and uses thereof

 #58
20200085890
2020-03-19

EXPRESSION OF PTEN-LONG WITH OCOLYTIC VIRUSES

 #59
20200071679
2020-03-05

Recombinant herpes simplex virus and use thereof

 #60
20200054737
2020-02-20

HERPES SIMPLEX VIRUS VACCINE

 #61
20200023058
2020-01-23

Recombinant herpes simplex virus 2 (HSV-2) vaccine vectors

 #62
20190359990
2019-11-28

Viral synthetic nucleic acid sequences and use thereof

 #63
20190330631
2019-10-31

Non-invasive method and kit for capturing and isolating fetal cells from mother

 #64
20190328644
2019-10-31

Recombinant nucleic acids encoding cosmetic protein(s) for aesthetic applications

 #65
20190300862
2019-10-03

Herpesvirus with Modified Glycoprotein H for Propagation in a Cell

 #66
20190276845
2019-09-12

NON-TOXIC HSV VECTORS FOR EFFICIENT GENE DELIVERY APPLICATIONS AND COMPLEMENTING CELLS FOR THEIR PRODUCTION

 #67
20190276507
2019-09-12

CODON OPTIMIZED NUCLEIC ACID ENCODING A RETINITIS PIGMENTOSA GTPASE REGULATOR (RPGR)

 #68
20190262410
2019-08-29

Oncolytic HSV vector

 #69
20190240321
2019-08-08

Passive transfer of immunity using recombinant herpes simplex virus 2 (HSV-2) vaccine vectors

 #70
20190111127
2019-04-18

Recombinant herpes simplex virus 2 (HSV-2) vaccine vectors

 #71
20190083555
2019-03-21

Construction of oncolytic herpes simplex viruses (oHSV) obligate vector and constructs for cancer therapy

 #72
20190046594
2019-02-14

HSV-1 oncolytic virus therapies that specifically kill ALT dependent cancers

 #73
20190040366
2019-02-07

Oncolytic virus strain

 #74
20190032024
2019-01-31

Engineered virus

 #75
20190022157
2019-01-24

Use of an oncolytic virus for the treatment of cancer

 #76
20190015466
2019-01-17

Modified oncolytic virus

 #77
20180339004
2018-11-29

Oncolytic viral vectors and uses thereof

 #78
20180155756
2018-06-07

Assay system to identify HPV replication inhibitors in HT-screen

 #79
20180133269
2018-05-17

Oncolytic HSV1 vector and methods of use

 #80
20180044643
2018-02-15

Non-neuroinvasive viruses and uses thereof

 #81
20170360857
2017-12-21

Stable Frozen Virus Formulation

 #82
20170319639
2017-11-09

ONCOLYTIC VIRUSES & METHODS OF USE THEREOF

 #83
20170274025
2017-09-28

Oncolytic HSV vector

 #84
20170202952
2017-07-20

Recombinant herpes simplex virus 2 (HSV-2) vaccine vectors

 #85
20170189514
2017-07-06

Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-HSV receptors

 #86
20170166617
2017-06-15

CODON OPTIMIZED NUCLEIC ACID ENCODING A RETINITIS PIGMENTOSA GTPASE REGULATOR (RPGR)

 #87
20170081659
2017-03-23

Compositions and methods for immunodominant antigens

 #88
20170035819
2017-02-09

Oncolytic HSV vector

 #89
20170028058
2017-02-02

HERPES SIMPLEX VIRUS VACCINES

 #90
20170023586
2017-01-26

Compositions and methods for immunodominant antigens of

#91
20160355789
2016-12-08

Virion display array for profiling functions and interactions of human membrane proteins

 #92
20160250267
2016-09-01

Oncolytic HSV vector

 #93
20160175370
2016-06-23

Targeting of herpes simplex virus to specific receptors

 #94
20160158343
2016-06-09

Recombinant herpes simplex virus 2 (HSV-2) vaccine vectors

 #95
20160153000
2016-06-02

Non-toxic HSV vectors for efficient gene delivery applications and complementing cells for their production

 #96
20160074448
2016-03-17

Herpes simplex virus (HSV) with modified tropism, uses and process of preparation thereof

 #97
20160000903
2016-01-07

Neuroattenuated herpes simplex virus

 #98
20150168401
2015-06-18

Compositions and methods for immunodominant antigens of

#99
20150139954
2015-05-21

Recombinant herpes virus and pharmaceutical composition containing the same

 #100
20140314811
2014-10-23

Herpes simplex virus vaccines

 #101
20120263752
2012-10-18

Herpes simplex virus vaccines

 #102
20120142555
2012-06-07

Compositions and methods for immunodominant antigens of

#103
20120141418
2012-06-07

Treatment of Melanoma Using HSV Mutant

 #104
20110318268
2011-12-29

Herpes simplex virus (HSV) with modified tropism, uses and process of preparation thereof

 #105
20110245099
2011-10-06

Compositions and methods for immunodominant antigens of

#106
20110195053
2011-08-11

Treatment of Non-Neuronal Cancer using HSV-1 Variants

 #107
20100172872
2010-07-08

Treatment of melanoma using HSV mutant

 #108
20100119535
2010-05-13

Compositions and methods for immunodominant antigens

 #109
20090285847
2009-11-19

Compositions and methods for immunodominant antigens of

#110
20070292394
2007-12-20

TREATMENT OF NON-NEURONAL CANCER USING HSV-1 VARIANTS

 #111
20050260169
2005-11-24

Treatment of cancer using HSV mutant

 #112
20050226850
2005-10-13

Treatment of non-neuronal cancer using HSV-1 variants

 #113
15218057
2018-03-20

Herpes simplex virus vaccine compositions and methods of production and use thereof